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A clone is defined as a population of cells derived
through mitotic division of a single somatic cell of ori-
gin. Accordingly, a tumour represents the clonal prog-
eny of a transformed somatic cell that has undergone
somatic gene mutations [1-3]. Several methods are
available nowadays to study tumour clonality, including
immunogenotyping in lymphoid tumours, assessment
of clonal loss of heterozygosity in many different neo-
plasms or clonal X-inactivation analysis in cellular pro-
liferations of female patients (reviewed in [3]). At a
superficial glance one might assume that a clonal tu-
mour would necessarily exhibit a homogeneous genetic
composition with regard to such genetic alterations.
However, tumours are typically very heterogeneous in
different respects. Look at a stained histologica] section
of a tumour, and you will notice that its morphological
appearance changes between areas as does the expres-
sion of immunological markers. Look at a leukaemic
karyotype, and you will notice that in addition to typi-
cal marker chromosomes present in most if not all
mitotic figures, additional non-random chromosomal
abnormalities might be present in smaller numbers of
cells, indicating the presence of distinct subpopula-
tions. Cells belonging to a tumour may vary greatly in
their capacity to metastasize, and a parent tumour,
albeit clonal, is heterogeneous, containing various sub-
clones with different metastatic potentials [4-7]. How,
one wonders, can the concept of tumour clonality be
reconciled with the notion of tumour heterogeneity?
It is important to return to the definition of a clone,
which clearly does not imply that a tumour must be
genetically or phenotypically homogeneous. A tumour
is thought to arise from a single somatic cell present in
normal tissue which, through the acquisition of gene
mutations, has been turned into an early founder cell of
the tumour clone (Figure 1). Examples of such early
events are the BCR-ABL translocation in chronic
myelogenous leukaemia (CML) which, if introduced
into normal murine haematopoietic stem cells, is suffi-
cient to launch a myeloproliferative disorder in mice [8,
9]. In colo-rectal cancers mutations in the familial
adenomatous polyposis (FAP) gene may turn up in
dysplastic aberrant crypt foci and in very early colo-
rectal adenomas assuming a gate-keeper role in tu-
mourigenesis [10]. Within such founder' clones
daughter cells will subsequently acquire additional
mutations and will thus be equipped with additional
chances of selection and proliferative advantages [1,11,
12]. They would thus establish their progeny as sub-
clones derived from a proximate parent clone and may
in turn become parent clones themselves [13, 14].
Colo-rectal cancers have become a citation classic in
this respect [10, 15). The pathway from normal intes-
tinal mucosa via adenoma to infiltrative and finally
metastatic carcinoma is plastered with step-wise accu-
mulation of somatic mutations which may hit many dif-
ferent genes (including the p53 tumour suppressor
gene, a gene called Deleted in Colo-rectal Carcinoma
[DCC], and many others). Before discussing the clonal
composition of a tumour it would therefore be essential
to define the mother cell that forms its starting point,
which is recognized by a particular clonal marker.
Within a model of multi-step accumulation of gene
mutations in tumour development, a clone is allowed to
begin wherever one wishes it to do so with the proviso
that any such wishes would have to be clearly stated [3,
13, 14]. To be more specific: we may choose as the
founder cell of a clone a member of another clone with
an earlier starting point, in which case the clone of
interest would be a subclone of the earlier one. This
concept is important in carcinogenesis and provides
the clue for reconciling tumour clonality and hetero-
geneity (Figure 1). An analysis of the clonal composi-
tion of tumours must therefore take into account the
following aspects:
a) an indication of the founder cell detected by a
particular marker used for assessing tumour clon-
ality;
b) the spatial distribution of subclones within a tu-
mour, particularly in solid tumours;
c) clonality assessment may only provide informa-
tion about the situation at the time of the analysis.
122
Figure 1. A schematic representation: The clonal evolution of a
human tumour governed by multistep accumulation of somatic
mutations. A normal somatic cell N (for example, a mucosal cell in
the gut) may be hit by a somatic mutation (arrow 1) and starts to
expand clonally. A cell present in this initial clone 1 may acquire an
additional mutation (arrow 2), and subclone 2 which is related to,
but distinct from, the initial clone may emerge. Subsequent muta-
tions (marked 3 and 4) may contribute to yet further heterogeneity
within this tumour where the initial mutation 1 marking the founder
clone is nevertheless retained. Molecular assessment of the clonal
composition of this rumour may yield different results, depending
on the time of analysis, the sample selected and the marker battery
used. If samples A comprising all subclones and samples B (a
tumour 'excerpt') are studied with marker 1, both tumour samples
will appear monoclonal and homogeneous. If sample B is analysed
with marker 4, the result will be negative, since this subclone does
not contain mutation 4. If the detection of mutation 4 provides
important prognostic information, sample B may not be represen-
tative of the tumour and the prediction of the patient's outcome.
The clonal composition of a tumour may change
in the course of its history.
The simple corollaries of these principles are often
ignored in the interpretation of molecular assessment
of tumour clonality. It seems useful to examine a few
selected examples in order to recognize the impact of
molecular tumour heterogeneity on conclusions to be
drawn from DNA analyses using molecular tumour
markers.
Multiple tumour lesions in an organ: Derived from one
or several different founder cells?
A variety of tumours typically present as multifocal
lesions rather than as a contiguously spreading tumour
mass. Examples are multifocal breast carcinoma, can-
cers in the urinary bladder, ovarian cancer involving
the peritoneal cavity or hepatocellular carcinoma. It is
often impossible morphologically to distinguish be-
tween simultaneously occurring tumours of independ-
ent origin, and tumour lesions with a common clonal
'mother' focus whose progeny subsequently spread in a
multifocal fashion. Genetic markers assessing clonality
of such lesions in a comparative way have thrown some
interesting light on this problem.
In patients with urinary bladder cancer multiple tu-
mours scattered over the bladder epithelium are often
identified at cystoscopy. Such observations have given
rise to the concept of field defects' or field canceri-
sation' whereby carcinogenic agents would affect many
different susceptible cells, resulting in their more or less
simultaneous transformation. This in turn would lead
to the development of multiple clonally distinct tu-
mours. Conversely, multifocal tumours might have
arisen via spread of tumour cells derived from a com-
mon progenitor lesion. There is no way to differentiate
between these two options by morphological criteria.
Multifocal tumour lesions in the bladder of a given
patient often contain identical patterns of clonal
X-inactivation, and show loss of the same allele on
chromosome 9q where an as yet unidentified tumour
suppressor gene operative in early bladder cancer de-
velopment is thought to reside [16, 17]. These findings
suggest a common clonal origin of multifocal bladder
tumour lesions rather than an independent, truly multi-
centric origin. In the same tumours a search for loss of
heterozygosity on chromosomes 17p and 18q, how-
ever, may reveal patterns that in a given patient differ
between geographically separate lesions, indicating dis-
parate clonal evolution in such daughter tumours.
Ovarian cancer has been studied in a similar fashion.
Using p53 gene mutations as a marker, evidence for a
common clonal origin of ovarian cancer presenting
with multifocal involvement of the peritoneum has
been obtained [18, 19]. A different genetic marker sys-
tem, for example DNA fingerprinting, may demon-
strate that within an individual patient the primary
ovarian tumour and peritoneal metastases share a basic
clonal DNA fingerprint pattern with additional varia-
tions between different sites, indicating different tu-
mour subpopulations derived from a common stem
line [18-21]. In contrast, papillary serous carcinoma of
the peritoneum which is morphologically indistinguish-
able from papillary serous carcinoma of the ovary may
represent a truly multifocal tumour, at least in some
cases [22].
Hepatocellular carcinoma sometimes presents with
multiple tumour nodules in the liver, posing the differ-
ential diagnosis between cancers of truly multicentric
and those of metastatic origin within the liver. Depend-
ing on the molecular marker used, either possibility
seems to occur. Clonal p53 gene mutations [23] or
DNA fingerprint alterations [24] may either be shared
by all lesions, indicating a common clonal origin with
subsequent spread, or may show heterogeneous pat-
terns.
An interesting problem is the clonal analysis of
multicentric/multifocal breast cancer or assessment of
clonality in ductal carcinoma in situ (DCIS) and inva-
sive ductal cancer present in the same breast Allelic
loss identified in DCIS lesions usually persists in the
synchronous invasive ductal breast cancer foci and
regional lymph node metastases [25], indicating that in
all likelihood the invasive component is derived from
the DCIS. LOH at other loci, for example at l ip , may,
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however, be restricted to invasive cancer and may thus
represent a later event on the pathway to invasion.
Several reports on multifocal/multicentric invasive
breast cancer have either confirmed [26] or refuted [27]
the notion that such lesions represent truly independ-
ent, separate clonal tumours.
Differences in the choice of DNA markers must be
appreciated when interpreting such analyses. The
detection of a clonal DNA marker common to all areas
of a tumour or a molecular tag consistently present in
several anatomically separate tumour lesions in an
organ may duly be interpreted as evidence of their
common clonal origin. For example, assessment of
clonality by X-inactivation analysis is based on inacti-
vation of either the paternal or the maternal X-chromo-
some copy in a given cell and thus represents a marker
which preexists in early transformed founder cells of
malignant tumours, since X-inactivation patterns in
particular cells or tissues are established in early
embryogenesis. Therefore, clonal X-inactivation analy-
sis provides insight into an early phase of carcino-
genesis and represents an 'early marker' of the clonal
relation of different tumour lesions [28]. If a marker
captures a 'late' genetic event, it is conceivable that
separate tumour lesions in an organ show disparate
patterns whilst still being clonally related by virtue of
sharing identical X-inactivation patterns. For example,
clonal loss of heterozygosity traced by polymorphic
DNA markers (variable-number-of-tandem-repeat
markers or microsatellites) may occur at any stage of a
multi-step accumulation of genetic mutations in an
evolving cancer [10, 15, 23, 29]. Heterogeneity with
respect to such a DNA marker between various syn-
chronous but geographically separate tumour lesions is
no definite proof of their truly multifocal and inde-
pendent clonal origin, since such tumours, although
genetically heterogeneous, might still be clonally relat-
ed as subclones of a common lesion of origin [16]. In
summary, multifocal/multicentric tumour lesions in an
organ are often clonally related, and molecular hetero-
geneity between various such foci is no definite proof
of their clonally independent development
Post-transplantation lymphoproliferative disorders
(PT-LPD) may be an interesting exception to this rule
of thumb [30-35]. These tumours often present as syn-
chronous multiple lymphomas, mostly of B-cell pheno-
type. If separate PT-LPD lesions of an immunosup-
pressed transplant patient are examined for their clonal
composition with appropriate markers such as Ig gene
rearrangements or patterns of Epstein-Barr virus ter-
minal-repeats [36], distinct patterns will be noted with
respect to both markers. Separate PT-LPD lesions
occurring synchronously in a single organ or patient
may often represent multiple independent primary
lymphoid proliferations rather than haematogeneous
spread of a single clone disorder as in 'conventional'
malignant lymphoma.
Hodgkin's disease (HD) has always presented a par-
ticularly intriguing problem with respect to clonality. A
recent report focussed on the detailed analysis of re-
arranged immunoglobulin variable-region heavy-chain
(VH) genes in single Reed-Sternberg cells picked under
microscopic control from lymph nodes involved with
Hodgkin's lymphoma [37]. Assessment of tumour
heterogeneity was thus brought down to the single cell
level. Three patterns were observed: identical VH re-
arrangements in all cells from a HD lymphoma, indi-
cating a common monoclonal origin of these Reed-
Sternberg cells, possibly from a naive or memory
B-cell; unrelated and unique VH rearrangements, indi-
cating a polyclonal origin of these cells; and a combina-
tion of the two. These findings point to a possibly dis-
tinct pathogenesis of either polyclonal or monoclonal
HD.
The spatial distribution of subclones within a tumour,
molecular tumour diagnosis and the pitfall of sampling
Molecular genetic abnormalities in tumours are of im-
mense interest in basic science, but molecular markers
are also being increasingly used in translation^ re-
search and in the clinic. In many common cancers we
are still looking for improvement in assessing the prog-
nosis of individual cases in the hope of being able
to tailor management, particularly treatment. Particu-
lar gene mutations are not simply surrogate markers for
biological behaviour but often represent the actual
driving forces underlying neoplastic growth. One thus
hopes that their detection would refine and sharpen
our diagnostic armamentarium, because molecular tu-
mour typing would permit the sorting out of defined
tumour entities within morphologically defined groups
of tumours of heterogeneous molecular composition.
Let us pick a frequent and well studied example: colo-
rectal adenocarcinomas presenting in Dukes stage B
without discernible involvement of regional lymph
nodes comprise a mixed bag of cases with rather vari-
able clinical courses. The study of these cancers for loss
of heterozygosity (LOH) with polymorphic microsatel-
lite markers from the long arm of chromosome 18
(18q) shows that slightly less than half of them show
LOH (18 q-) and the remainder retain a normal chro-
mosome 18q status. The presence or absence of this
marker appears to be highly correlated with outcome,
since the survival rate of patients with Dukes B / 18q-
tumours is similar to that of patients with Dukes C
node-positive disease [38]. Patients with Dukes B tu-
mours which retain a normal 18q configuration enjoy a
significantly better outcome. In practice such molecular
analyses are often performed on single small biopsy
specimens taken from large lesions. Interpretation of
the results must take into account the question of
whether a tumour specimen is truly representative of
the entire tumour. This is the point where molecular
tumour heterogeneity due to clonal evolution comes in.
'Early5 mutations, for example those with a gate-keeper
function in tumour development, may be expected to
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be present throughout the tumour because they must
have arisen in an early founder cell. Mutations restrict-
ed to particular tumour subclones, however, are not
necessarily present throughout the cancer but possibly
restricted to particular geographical tumour areas. We
looked at this problem in a series of gastro-intestinal
cancers taken from female patients whereby several
geographically distinct tumour areas were examined
with a battery of clinically relevant molecular markers
[39]. The question of whether these tumours had arisen
from one or perhaps a few single mucosal founder cells
was tackled by clonal X-inactivation analysis [28]. Each
tumour (with one exception) showed a uniform clonal
X-inactivation pattern throughout all of the samples,
suggesting the cancer's origin in a single early mucosal
founder cell. However, LOH, for example at 18q and
clonal microsatellite mutations due to replication errors
in RER+ tumours [40-44] often differed considerably
between various morphologically defined areas from a
given tumour, indicating considerable clonal hetero-
geneity with respect to these markers. These mutations
most probably arose from an ancestral cell that was
already present in the tumour and in turn became the
founder of a particular subclone identified by these
molecular tags. Molecular analyses based on such
markers should be interpreted with caution because
sampling errors in cancers with clonal intratumour
heterogeneity will affect the results. Tumour subclones
bearing a particular marker may be missed in the speci-
men selected for analysis and yet they may behave dif-
ferently from tumour tissue represented in the biopsy
analysed [39, 45]. Accordingly, metastatic foci of such
cancers, for example in the liver, may harbour molecu-
lar abnormalities that are not readily detectable
throughout the corresponding primary tumours [46].
In prostate cancer radical prostatectomy specimens
provide an opportunity to look at the intratumour
clonal composition of this common type of tumour. In
addition to dominant cancer nodules, separate smaller
tumour foci are often observed to exhibit different his-
tological grades. Within a prostate cancer there may be
tumour subpopulations which manage to implant their
progeny into regional lymph nodes whilst other sub-
clones such as foci of well differentiated carcinoma may
be indolent In addition, lesions representing prostatic
intraepithelial neoplasia (PIN) which correspond to
non-invasive in situ tumour lesions may be present.
Microdissection of prostate cancer specimens permits
separate molecular mapping of such diverse lesions
and their genetic markers [47, 48]. Candidate genetic
markers include deleted gene sequences or LOH on
chromosome 8p, lOq and 16q. A detailed molecular
analysis will reveal that the morphological hetero-
geneity in prostate neoplasias and premalignant lesions
is reflected at the molecular level. Separate PIN lesions
may show different clonal patterns of allelic loss at
8p 12-21, suggesting that they may arise independently
of one another [48, 49]. When comparing metastatic
cancer foci in regional lymph nodes with various indi-
vidually microdissected lesions in a prostate, the mo-
lecular genetic relationship of metastatic tumour to one
or the other of the primary tumour foci may be traced.
It is of interest to note that allelic loss patterns may not
always identify the morphologically-dominant primary
prostate tumour as the source of metastases; on occa-
sion such genetic links rather point to additional tu-
mour foci as the origin of lymph node metastases.
Looking at a snapshot when really you should watch a
film
The clonal composition of a neoplasm must be viewed
as a dynamic process which may undergo considerable
alteration over time. The analysis of a solid tumour or a
haematological neoplasm with an appropriate battery of
molecular markers can only be interpreted correctly
when the effects of clonal evolution leading to molecu-
lar heterogeneity of the tumour are duly appreciated.
Leukaemias harbour specific (even individual-specific)
clonal markers which are amenable to amplification
with the rapid and sensitive polymerase-chain reaction
(PCR). If the 'traditional', relatively insensitive means of
following patients treated for leukaemia are used to
define remission, a considerable undetected leukaemic
burden usually remains in the patient's organism which
will ultimately result in clinical relapse. The PCR now
offers a much more sensitive follow-up by amplifying
leukaemia-specific markers such as the BCR-ABL
transcript in CML [50, 51], or the fusion messenger
RNA derived from the DNA stretch bridging chromo-
some 15 (bearing the so-called mv//PML gene) and
chromosome 17 (harbouring the retinoic acid receptor
a gene) in acute promyelocytic leukaemia [52-55]. In
acute lymphoblastic leukaemia (ALL) individual-spe-
cific clonal immunoglobulin (Ig) or T-cell receptor gene
rearrangements may provide templates for preparing
patient-tailored molecular probes which can pick up
minimal numbers of residual leukaemic cells in remis-
sion marrow [56-67]. Successful follow-up using mo-
lecular markers depends on the question of whether
leukaemic cells would retain a stable composition of
diagnostic molecular markers or whether clonal
evoluation within the original leukaemic clone would
eventually lead to molecular heterogeneity and diag-
nostic difficulties, particularly false-negative results
[58, 67-69]. In CML the BCR-ABL fusion gene pro-
vides a til rouge' which can be traced through the
course of disease. An interesting case of CML in a
patient who developed myeloid blast crisis after six
years of chronic phase was recently reported [70].
Whilst the BCR-ABL marker which had been present
throughout the chronic phase still persisted, a consid-
erable population of malignant cells in blast crisis had
acquired a new clonal marker, a point mutation in the
p53 tumour suppressor gene. The patient responded to
chemotherapy and a second chronic phase was induced
in which the p53 mutation was no longer detectable in
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the malignant blasts. A few months later, there was a
second blast crisis, apparently involving a different
CML subclone, since the p53 mutation that had
marked the first blast crisis remained undetectable. The
original clonal BCR-ABL marker still remained. This
case is a good example of the fact that the clonal com-
position of a neoplasm may change over time, with new
clonal markers coming up at defined stages which may
either persist or vanish again. The molecular marker
pattern of a neoplasm can be flexible and hetero-
geneous in a time-dependent manner. Assessment of
clonality with a particular marker will yield different
results, depending on when the analysis is made.
Molecular follow-up of patients with acute lympho-
blastic leukaemia provides another example of how the
dynamics affecting gene mutations in cancer over time
may affect molecular diagnostics. In each patient Ig
gene rearrangements in the malignant lymphoid cells
are clone-specific and contain unique base sequences.
It has been suggested that these can be cloned and then
used as custom-tailored probes for the sensitive detec-
tion of minimal residual leukaemia in remission mar-
row [61-68]. However, Ig gene rearrangements are not
necessarily stable in the leukaemic cells and gene
sequences may change because of ongoing somatic
mutations. For example, accumulation of point muta-
tions and insertion of extra nucleotides in Ig gene vari-
able regions may be extensive [71-74]. As a con-
sequence, leukaemic subclones emerging at relapse will
not entirely reflect the clonal composition of malignant
cells present at diagnosis. In practice, such subclones
will not be detected with clone-specific probes pre-
pared from diagnostic specimens obtained at presen-
tation.
Lymphomas of low grade malignancy often convert
into lymphomas of more aggressive clinical behaviour
which on morphology may look quite distinct from
samples obtained at initial diagnosis. For example, fol-
licular lymphoma may evolve into diffuse large-cell
lymphoma. Assessment of the clonal relationship be-
tween such morphologically distinct lesions seen in the
same patient nicely illustrates that the study of then-
molecular composition must reckon with molecular
heterogeneity. Results will therefore depend on which
DNA markers are used at a given time. Follicular lym-
phoma is usually characterized by the translocation
t(14;18) which fuses parts of the Ig heavy-chain gene
on chromosome 14 with the BCL-2 gene on chromo-
some 18. Analysis of the bridging DNA sequences at
the t(14;18) junction reveals that this marker usually
persists throughout the course of the disease, including
transformation into a highly malignant lymphoma [73-
77]. By simply looking at this marker, one might
erroneously conclude that the molecular composition
of the original clone remains unchanged. Analysis of a
second clonal marker, i.e., rearranged Ig heavy-chain
genes, reveals a molecular model to mirror transforma-
tion identified by morphology. The initial clone (a
mother clone, as it were) remains stably marked by the
t(14;18) translocation present in its founder cell. As a
result of ongoing somatic hypermutation in rearranged
Ig genes, the B-cell tumour population nevertheless
becomes heterogeneous with individual clonally relat-
ed subclones tagged by specific rearranged Ig variable
regions [73-80]. Serial analysis of such sequences per-
mits the construction of a genealogical tree to portray
the clonal relationship present in a lymphoid neoplasm
tracing subclones which are evolutionally related, de-
rived from a common progenitor, but which still differ
because of different maturational histories. Some sub-
clones can be selected through therapy, or can overrule
others via a proliferative selection advantage [71, 74,
75]. In our example, the notion is that a transformed
malignant subclone presenting as large-cell lymphoma,
arises from the original follicular lymphoma clone
rather than representing the product of an independent
transforming event.
A recent detailed clonal analysis of Hodgkin's dis-
ease of the lymphocytic-predominance subtype by
immunogenotype PCR revealed a clonal relationship
between various morphologically-related lesions [81].
Thus, in a lymph node, progressively transformed ger-
minal centres may represent precursor lesions of lym-
phocytic-predominance HD. They are mostly poly-
clonal and only a few of them become founder cells of
oligoclonal lesions morphologically recognized as lym-
phocytic-predominance HD. This state may persist for
years, but eventually additional genetic events may act
on one or the other of the B-cell subclones and cause
its preferential expansion and a monoclonal lymphoid
proliferation that appears on morphology as a mono-
clonal B-cell large-cell lymphoma.
These principles are not restricted to haematological
neoplasms, but apply also to the solid rumours. Glio-
mas may perhaps serve to illustrate this point. Astro-
cytomas (low-grade tumours) may evolve into faster
growing, more aggressive and invasive tumours, glio-
blastomas. This tumour progression may be associated
with the acquisition of clonal mutations within the p53
gene. If low-grade tumours are carefully analysed, sub-
populations of cells may be found that already contain
such p53 gene mutations which become predominant
in glioblastoma [82, 83]. A rare cell in an 'early1 lesion
carrying a specific change may thus become the domi-
nant cell type as the tumour progresses [84].
Conclusions
Molecular assessment of the clonal composition of
human neoplasms represents much more than just a
'complicated way of proving the obvious fact that
tumours are monoclonal'. A successful analysis must
take into account the geographical selection of tissue
samples, the choice of the DNA markers used to tackle
the problem, and their hierarchical position within a
chain of accumulated gene mutations and the time-
point in carcinogenesis when a tumour sample is har-
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vested. Clonal molecular tumour heterogeneity might
lead to sampling errors and thus to erroneous inter-
pretations of molecular analyses. Tumour subclones
emerging at relapse may not entirely reflect the clonal
composition of malignant cells present at diagnosis and
will not necessarily be detected with tumour-specific
markers suitable for pinpointing a tumour at the time
of presentation [39, 85, 86]. Furthermore, clonal
tumour heterogeneity must be considered when 'mo-
lecular5 treatment strategies, such as knocking out the
expression of key genes through antisense oligonucleo-
tides, molecular mending, sewing and stitching of
crucial gene mutations in cancer cells, and other con-
cepts of gene therapy [87, 88] are designed. The recog-
nition of molecular tumour heterogeneity, indicating
the coexistence of clonally-related subclones within a
tumour of common clonal origin is thus important both
theoretically and practically.
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